Cardax
Honolulu, US · Founded 2012 · Delaware corporation
Cardax is a consumer health company that markets ZanthoSyn, a physician-recommended astaxanthin dietary supplement aimed at inflammatory health. The company previously developed pharmaceuticals for inflammation-driven diseases and holds pre-clinical candidates for cardiovascular inflammation/dyslipidemia (CDX-101) and macular degeneration (CDX-301).
BiotechConsumerWellness & Fitness
Founders & leadership
Cardax was founded in 2012 by David G. Watumull.
DG
David G. WatumullFounder
NM
Nicholas MitsakosExecutive
JB
John B. RussellExecutive
DM
David M. WatumullNamed on SEC filing
FH
Frank HerringerNamed on SEC filing
JR
John RussellNamed on SEC filing
Board
TA
Terence A. KellyBoard director
GW
George W. Bickerstaff IIIBoard director
Reported raises · per SEC filings
Form D private placements$7.3M disclosed across 4 rounds · 2014–2021
▶$200KraisedSep 2021 · 5 investors · PharmaceuticalsRule 506(b)
▶$200KraisedSep 2021 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David G. WatumullExecutive Officer, Director
- David M. WatumullExecutive Officer
- Offering amount
- $500K
- Amount sold
- $200K
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedMay 2017 · 50 investors · PharmaceuticalsRule 506(b)
▶$1.5MraisedMay 2017 · 50 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John B. RussellExecutive Officer
- David G. WatumullExecutive Officer, Director
- Michele GalenDirector
- George W. Bickerstaff IIIDirector
- Terence A. KellyDirector
- Amount sold
- $1.5M
- Minimum investment
- $10K
- First sale
- May 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.6MraisedNov 2015 · 29 investors · PharmaceuticalsRule 506(b)
▶$1.6MraisedNov 2015 · 29 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David G. WatumullExecutive Officer, Director
- Nicholas MitsakosExecutive Officer, Director
- Terence A. KellyDirector
- George W. Bickerstaff IIIDirector
- John B. RussellExecutive Officer
- Offering amount
- $4M
- Amount sold
- $1.6M
- Minimum investment
- $10K
- Sales commissions
- $28.6K
- Placement agents
- Andrew Garrett, Inc.
- First sale
- Mar 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$3.9MraisedFeb 2014 · 62 investors · PharmaceuticalsRule 506(b)
▶$3.9MraisedFeb 2014 · 62 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David M. WatumullExecutive Officer
- David G. WatumullExecutive Officer, Director
- Frank HerringerDirector
- John RussellExecutive Officer
- Nicholas MitsakosDirector
- Offering amount
- $3.9M
- Amount sold
- $3.9M
- Minimum investment
- $5K
- Sales commissions
- $530K
- Proceeds to insiders
- $55K
- Placement agents
- Portfolio Advisors Alliance, Inc., Agincourt Ltd.
- First sale
- Feb 2014
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapCyanotech8 shared keywordsCyanotech cultivates Hawaiian microalgae to produce products for health and nutrition, operating from a farm in Kailua-Kona with 90 acres of cultivation ponds since 1984. The company focuses on sustainable, environmentally sensitive production of microalgae-based nutritional products.
Nutraceuticalbusinessreview8 shared keywordsNutraceutical Business Review is a trade media publication delivering news, interviews, technical reviews, trend reports and features covering the nutraceutical and supplements industry, from ingredients and packaging to regulation, retail and marketing. It reaches business leaders and decision-makers globally through digital, print and live products, including a magazine and industry conferences.
Companies competing with Cardax for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Cardax do?
- Cardax is a consumer health company that markets ZanthoSyn, a physician-recommended astaxanthin dietary supplement aimed at inflammatory health. The company previously developed pharmaceuticals for inflammation-driven diseases and holds pre-clinical candidates for cardiovascular inflammation/dyslipidemia (CDX-101) and macular degeneration (CDX-301).
- Who founded Cardax?
- Cardax was founded by David G. Watumull in 2012.
- How much funding has Cardax raised?
- Cardax has disclosed $7.3M raised across 4 rounds.
- Where is Cardax headquartered?
- Cardax is headquartered in Honolulu, US.